|
US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
|
US5260223A
(en)
*
|
1986-07-03 |
1993-11-09 |
President & Fellows Of Harvard College |
Methods for detection of human gamma, γ T cell receptor
|
|
ATE122238T1
(en)
*
|
1987-06-10 |
1995-05-15 |
Dana Farber Cancer Inst Inc |
BIFUNCTIONAL ANTIBODY CONSTRUCTIONS AND METHOD FOR SELECTIVE KILLING OF CELLS.
|
|
CA1338518C
(en)
*
|
1987-09-23 |
1996-08-13 |
Joyce M. Zarling |
Antibody heteroconjugates for the killing of hiv-infected cells
|
|
EP0334300A1
(en)
*
|
1988-03-21 |
1989-09-27 |
Neorx Corporation |
The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
|
|
FI105320B
(en)
*
|
1988-04-04 |
2000-07-31 |
Oncogen |
Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
|
|
EP0449879A1
(en)
*
|
1988-11-25 |
1991-10-09 |
Centocor, Inc. |
Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
ES2096590T3
(en)
*
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
|
|
US5897861A
(en)
*
|
1989-06-29 |
1999-04-27 |
Medarex, Inc. |
Bispecific reagents for AIDS therapy
|
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
|
US5945311A
(en)
*
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
|
DE122009000068I2
(en)
*
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Process for the preparation of heterologous bispecific antibodies
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
ES2169299T3
(en)
|
1996-09-03 |
2002-07-01 |
Gsf Forschungszentrum Umwelt |
PROCEDURE FOR THE DESTRUCTION OF CONTAMINANT TUMOR CELLS IN MOTHER CELL TRANSPLANTS USING SPECIFIC ANTIBODIES.
|
|
DK0826696T3
(en)
|
1996-09-03 |
2002-09-23 |
Gsf Forschungszentrum Umwelt |
Use of bi- and trispecific antibodies to induce a tumor immunity
|
|
WO2003015705A2
(en)
*
|
2001-08-17 |
2003-02-27 |
Roger Williams Hospital |
In situ immunization
|
|
WO2003040341A2
(en)
|
2001-11-07 |
2003-05-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-hepatitis a virus antibodies
|
|
AU2002356962C1
(en)
|
2001-12-12 |
2008-05-01 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
|
|
EP2158917A1
(en)
|
2002-09-19 |
2010-03-03 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
P.ariasi polypeptides, P.perniciosus polypeptides and methods of use
|
|
EP1572968B1
(en)
|
2002-10-29 |
2009-04-22 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Lutzomyia longipalpis polypeptides and methods of use
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
CA2602777C
(en)
|
2005-03-25 |
2018-12-11 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
AU2006261127B2
(en)
|
2005-06-17 |
2012-03-15 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
|
EP2441470B1
(en)
|
2006-03-14 |
2014-05-07 |
Oregon Health and Science University |
Methods for producing an immune response to tuberculosis
|
|
US7777008B2
(en)
|
2006-06-19 |
2010-08-17 |
Tolerx, Inc. |
ILT3 binding molecules and uses therefor
|
|
CA2678404C
(en)
|
2007-02-28 |
2019-03-19 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
|
ES2591281T3
(en)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Combination therapies that employ GITR binding molecules
|
|
AU2009294850B2
(en)
|
2008-09-22 |
2015-07-02 |
Oregon Health & Science University |
Methods for detecting a Mycobacterium tuberculosis infection
|
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
|
CA2766220C
(en)
|
2009-06-26 |
2021-02-09 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
|
CN102713629B
(en)
|
2009-11-20 |
2016-02-24 |
俄勒冈健康科学大学 |
Method for detecting Mycobacterium tuberculosis infection
|
|
TW201217527A
(en)
|
2010-07-09 |
2012-05-01 |
Biogen Idec Hemophilia Inc |
Processable single chain molecules and polypeptides made using same
|
|
CA2808482C
(en)
|
2010-08-16 |
2021-10-26 |
Novimmune S.A. |
Methods for the generation of multispecific and multivalent antibodies
|
|
CA2809864A1
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
|
EP2524699A1
(en)
|
2011-05-17 |
2012-11-21 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
|
EP2709655B1
(en)
|
2011-05-17 |
2018-11-14 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
|
CA2838833A1
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
WO2013022782A1
(en)
|
2011-08-05 |
2013-02-14 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
|
EP2748198A2
(en)
|
2011-09-27 |
2014-07-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
|
CA2860579A1
(en)
|
2012-01-10 |
2013-07-18 |
Biogen Idec Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
|
WO2013152352A1
(en)
|
2012-04-06 |
2013-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Live, attenuated rubella vector to express vaccine antigens
|
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
|
WO2014046730A1
(en)
|
2012-09-24 |
2014-03-27 |
Ventana Medical Systems, Inc. |
Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
|
|
ES2639559T3
(en)
|
2012-12-28 |
2017-10-27 |
Ventana Medical Systems, Inc. |
Image analysis for breast cancer prognosis
|
|
WO2014164472A1
(en)
|
2013-03-10 |
2014-10-09 |
The Board Of Regents Of The University Of Texas System |
Biomarkers for chagas disease related cardiomyopathy
|
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
|
WO2015199976A1
(en)
|
2014-06-24 |
2015-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Target activated microdissection
|
|
AR101262A1
(en)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
PURIFICATION PLATFORM FOR Bispecific Antibodies
|
|
JP6796058B2
(en)
|
2014-08-08 |
2020-12-02 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Light-controlled removal of targets in vitro and in vivo
|
|
US11014088B2
(en)
|
2016-03-09 |
2021-05-25 |
The Board Of Regents Of The University Of Texas System |
Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
|
|
WO2019051041A1
(en)
|
2017-09-06 |
2019-03-14 |
University Of Cincinnati |
Methods of prognosing early stage breast lesions
|
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
AU2018347796B2
(en)
|
2017-10-10 |
2025-07-24 |
Medicenna Therapeutics, Inc. |
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
|
|
KR20250156861A
(en)
|
2019-05-21 |
2025-11-03 |
노파르티스 아게 |
Cd19 binding molecules and uses thereof
|
|
US20220214332A1
(en)
|
2019-05-30 |
2022-07-07 |
Oregon Health & Science University |
Methods for Detecting A Mycobacterium Tuberculosis Infection
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
WO2024044687A1
(en)
|
2022-08-26 |
2024-02-29 |
Valo Health, Inc. |
Biomarker combinations for prognosis and management of diabetic retinopathy
|